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Tumor necrosis factor (TNF) was discov-
ered in 1975 as a lipopolysaccharide-
induced serum factor that causes necrosis
of tumors (Carswell et al, 1975). It was
later found that TNF and cachectin, a
factor causing wasting disease, were one
and the same molecule (Beutler et al,
1985). Studies on the inflammatory activ-
ity of TNF have been translated into clini-
cal success, namely blocking antibodies
used to suppress autoimmune diseases.
Research on TNF anti-tumor activity, in
contrast, has not yet resulted in a thera-
peutic breakthrough. This may change,
based on a study by Huyghe et al (2020)
describing novel “designer cytokines”
(TNF and interferon-c) that increase local
activity by targeting the CD13-positive
tumor vasculature, while simultaneously
lowering the binding affinity to the
respective cytokine receptor, thereby
reducing off-target effects on normal
cells.
EMBO Mol Med (2020) 12: e11801
See also: L Huyghe et al (February 2020)
T umor necrosis factor (TNF) and inter-feron-c (IFNc) are essential to rejectsolid tumors and act both on tumor
and stromal cells. In fact, the anti-tumor
effects of TNF and IFNc on activated
tumor vasculature are probably the reason
why immunotherapy using T cells can
destroy solid tumors that are refractory to
cytotoxic therapies (Kammertoens et al,
2017). Because anti-tumor effects of TNF
and IFNc had been observed in pre-clinical
models, both cytokines were tested in the
clinic when recombinant proteins became
available. However, severe systemic
toxicities limited their clinical use (Fig 1A).
The therapeutic potential of high doses of
TNF and IFNc in humans could only be
demonstrated upon shielding of the organ-
ism from systemic toxicity via separation
of the circulation of a cancer-affected limb
from the rest of the body, a procedure
called “isolated limb perfusion” (ten Hagen
et al, 2008).
Two different strategies have been devel-
oped to reduce systemic toxicity of TNF or
IFNc while preserving their anti-tumor activ-
ity. The first one consists in specifically
targeting the cytokines to CD13, a marker
predominantly expressed on tumor vascula-
ture. Targeting was achieved using either
peptides or single-chain antibodies directed
against CD13 (Fig 1B). Pre-clinical data
suggest that such approaches are feasible
and may improve local therapeutic anti-
tumor activity (Johansson et al, 2012; Corti
et al, 2013). The second strategy to reduce
unwanted side effects is based on changing
the molecular interactions between TNF or
IFNc and their receptors. A prime example
of such a strategy is the study by Mendoza
et al (2019) in which, based on the crystal
structure of the IFNc signaling complex,
specific signaling agonists were designed by
changing contact residues between the
ligand and receptor chains, resulting in a
molecule with reduced side effects for
immunotherapy.
In their study, Huyghe et al (2020) have
combined both strategies and thus improved
efficacy and safety for the therapeutic use of
TNF and IFNc (Huyghe et al, 2020). First,
they succeeded in increasing the local cyto-
kine concentration at the tumor site by
attaching a CD13-specific single-chain anti-
body to the cytokines. Second, they mutated
TNF (by changing amino acid 87 Y to F) and
IFNc (by truncating 8 C-terminal amino
acids), thereby reducing the biological activ-
ity approx. 10,000- and 7,000-fold, respec-
tively. This resulted in decreased systemic
toxicity (Fig 1C). The novel TNF could also
improve adoptive T-cell therapy using T
cells engineered with chimeric antigen
receptors by increasing the number of T
cells infiltrating the tumor. In mice with
endothelial-specific TNFR1 expression,
tumors could be eradicated without measur-
able toxicity. However, tumor-activated
vessels are not the only ones highly suscep-
tible to the destructive TNF effects, also
vessels exposed to bacterial products react
strongly to TNF with systemic or local
Schwarzman reactions (Rothstein &
Schreiber, 1988). It would therefore be
important to test whether endothelial cells
that are activated during bacterial infections
could become CD13-positive targets of the
novel designer cytokines. Finally, it should
be mentioned that there is a third powerful
strategy to locally release therapeutic
amounts of TNF and IFNc, which is the
transfer of tumor antigen-specific T cells that
release the cytokines upon antigen
encounter.
Clinical studies that specifically direct
cytokines such as TNF or IFNc to the
tumor endothelium via peptides or single-
chain antibodies are already underway.
Huyghe et al’s elegant approach, however,
makes it possible to concentrate the effect
of the cytokines more precisely to the
tumor site, thereby increasing the thera-
peutic effect and avoiding negative side
effects and systemic toxicity. Therefore,
this work is certainly an important step
forward for the development of “designer
cytokines” that are suitable for clinical
application.
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Figure 1. Strategies to use TNF as an anti-cancer agent.
(A) Using recombinant tumor necrosis factor (TNF) that binds to the TNF receptor (TNFR) on all cells in the body
causes toxicity and prohibits clinical application. (B) Fusing TNF to a single-chain antibody targeting
CD13 that is preferentially expressed on tumor vasculature concentrates its activity to the tumor site but does
not exclude off-target effects as it still binds to TNFR on all other cells in the body. (C) The novel “designer
cytokine” approach developed by Hyghe et al combines selective targeting of TNF to the tumor
vasculature using a CD13-specific single-chain antibody and mutating the TNF molecule (Y87F) to decrease the
binding to TNFR and avoid systemic toxicity.
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